T cell depletion in paediatric stem cell transplantation

Clinical and Experimental Immunology

Volumn 172, Issue 2, 2013, Pages 139-147

  Booth, C ^a   Veys, P ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Paediatric; Stem cells; T cells

Indexed keywords

ALEMTUZUMAB; CASPASE 9; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; MELPHALAN; METHOTREXATE; OKT 3; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THIOTEPA; THYMIDINE KINASE;

ARTICLE; CD3+ T LYMPHOCYTE; CD34 SELECTION; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; DENDRITIC CELL; DISEASE FREE SURVIVAL; ENGRAFTMENT; EX VIVO STUDY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOTHERAPY; IN VIVO STUDY; INFECTION RISK; INNATE IMMUNITY; LEUKEMIA; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; MORTALITY; NATURAL KILLER CELL; OVERALL SURVIVAL; PEDIATRICS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUICIDE GENE THERAPY; T CELL DEPLETION; TRANSPLANTATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD TRANSPLANTATION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ANTIGENS, CD34; CHILD; DISEASE-FREE SURVIVAL; FETAL BLOOD; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84876095148     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12004     Document Type: Article

References (76)

1. Ho V, Soiffer RJ. T-cell depletion to prevent graft-vs-host disease. Totowa, NJ: Humana Press, 2004.
2. Rodt H, Kolb HJ, Netzel B etal. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc 1981; 13 (1 Pt 1):257-261.
3. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3192-3204.
4. Reisner Y, Kapoor N, Kirkpatrick D etal. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2:327-331.
5. Prentice HG, Blacklock HA, Janossy G etal. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982; 1:700-703.
6. Waldmann H, Polliak A, Hale G etal. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2:483-486.
7. de Witte T, Hoogenhout J, de Pauw B etal. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood 1986; 67:1302-1308.
8. Maraninchi D, Mawas C, Guyotat D etal. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation. Transpl Int 1988; 1:91-94.
9. Filipovich AH, Vallera D, McGlave P etal. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation 1990; 50:410-415.
10. Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990; 75:2076-2084.
11. Antin JH, Bierer BE, Smith BR etal. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78:2139-2149.
12. Wagner JE, Santos GW, Noga SJ etal. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a Phase I-II clinical trial. Blood 1990; 75:1370-1377.
13. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21:1387-1394.
14. Bacigalupo A, Lamparelli T, Bruzzi P etal. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98:2942-2947.
15. Jol-van der Zijde CM, Bredius RG, Jansen-Hoogendijk AM etal. IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplant 2012; 47:360-368.
16. Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49:2256-2262.
17. Rebello P, Hale G. Pharmacokinetics of Campath-1h: assay development and validation. J Immunol Methods 2002; 260:285-302.
18. Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GW. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation 1986; 41:220-229.
19. Dreger P, Viehmann K, Steinmann J etal. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or Campath-1. Exp Hematol 1995; 23:147-154.
20. Finke J, Brugger W, Bertz H etal. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18:1081-1086.
21. Urbano-Ispizua A, Solano C, Brunet S etal. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant 1998; 22:519-525.
22. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised Phase II-III trial. Lancet 2005; 366:733-741.
23. Lang P, Handgretinger R, Niethammer D etal. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 2003; 101:1630-1636.
24. Geyer MB, Ricci AM, Jacobson JS etal. T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. Br J Haematol 2012; 157:205-219.
25. Veys P, Wynn RF, Ahn KW etal. Impact of immune modulation with in vivo T cell depletion and myleoablative total body irradiation conditioning regimen on outcomes after unrelated donor transplantation for acute lymphoblastic leukemia in children. Blood 2012; 119:6155-6161.
26. Shah AJ, Kapoor N, Crooks GM etal. The effects of Campath-1h upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007; 13:584-593.
27. Myers GD, Krance RA, Weiss H etal. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36:1001-1008.
28. Soiffer RJ, Lerademacher J, Ho V etal. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117:6963-6970.
29. Shaw BE, Apperley JF, Russell NH etal. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol 2011; 153:244-252.
30. Slatter MA, Rao K, Amrolia P etal. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011; 117:4367-4375.
31. Boelens JJ, Wynn RF, O'Meara A etal. Outcomes of hematopoeitic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40:225-233.
32. Rubinstein P, Carrier C, Scaradavou A etal. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565-1577.
33. Gluckman E, Rocha V, Boyer-Chammard A etal. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337:373-381.
34. Dalle JH, Duval M, Moghrabi A etal. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant 2004; 33:605-611.
35. Eapen M, Rocha V, Sanz G etal. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653-660.
36. Rocha V, Wagner JE, Jr, Sobocinski KA etal. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on alternative donor and stem cell sources. N Engl J Med 2000; 342:1846-1854.
37. Rocha V, Cornish J, Sievers EL etal. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962-2971.
38. Wagner JE, Barker JN, DeFor TE etal. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100:1611-1618.
39. Michel G, Rocha V, Chevret S etal. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102:4290-4297.
40. Chiesa R, Gilmour K, Qasim W etal. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012; 156:656-666.
41. Klingebiel T, Cornish J, Labopin M etal. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the acute leukemia and pediatric disease working parties of the European Blood and Marrow Transplant Group. Blood 2010; 115:3437-3446.
42. Aversa F, Tabilio A, Terenzi A etal. Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84:3948-3955.
43. Aversa F, Tabilio A, Velardi A etal. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186-1193.
44. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41:473-481.
45. Marks DI, Khattry N, Cummins M etal. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006; 134:196-201.
46. Handgretinger R, Klingebiel T, Lang P etal. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27:777-783.
47. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118:6006-6017.
48. Handgretinger R, Chen X, Pfeiffer M etal. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann NY Acad Sci 2007; 1106:279-289.
49. Mead AJ, Thomson KJ, Morris EC etal. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 2010; 115:5147-5153.
50. Brunstein CG, Fuchs EJ, Carter SL etal. Alternative donor transplantation after reduced intensity conditioning: results of parallel Phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118:282-288.
51. Bethge WA, Faul C, Bornhauser M etal. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40:13-19.
52. Bader P, Soerensen J, Jarisch A etal. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol 2011; 24:331-337.
53. Daniele N, Scerpa MC, Caniglia M etal. Transplantation in the onco-hematology field: focus on the manipulation of alphabeta and gammadelta T cells. Pathol Res Pract 2012; 208:67-73.
54. Lamb LS, Jr, Gee AP, Hazlett LJ etal. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy 1999; 1:7-19.
55. Godder KT, Henslee-Downey PJ, Mehta J etal. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39:751-757.
56. Perruccio K, Tosti A, Burchielli E etal. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106:4397-4406.
57. Feuchtinger T, Opherk K, Bethge WA etal. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116:4360-4367.
58. Comoli P, Schilham MW, Basso S etal. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 2008; 31:529-536.
59. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40:68-70.
60. Haque T, Wilkie GM, Jones MM etal. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131.
61. Qasim W, Derniame S, Gilmour K etal. Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol 2011; 154:150-153.
62. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2006; 37:297-305.
63. Ge X, Brown J, Sykes M, Boussiotis VA. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant 2008; 14:518-530.
64. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004; 103:1158-1165.
65. Samarasinghe S, Mancao C, Pule M etal. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 2010; 115:396-407.
66. Amrolia PJ, Muccioli-Casadei G, Huls H etal. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108:1797-1808.
67. Perruccio K, Topini F, Tosti A etal. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40:76-83.
68. Mielke S, Nunes R, Rezvani K etal. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008; 111:4392-4402.
69. Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 2009; 183:696-705.
70. Stuehler C, Mielke S, Chatterjee M etal. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 2009; 114:2829-2836.
71. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 Phase 1 studies. Blood 2008; 112:2232-2241.
72. Bonini C, Ferrari G, Verzeletti S etal. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276:1719-1724.
73. Ciceri F, Bonini C, Stanghellini MT etal. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised Phase I-II study. Lancet Oncol 2009; 10:489-500.
74. Di Stasi A, Tey SK, Dotti G etal. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-1683.
75. Brunstein CG, Miller JS, Cao Q etal. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061-1070.
76. Di Ianni M, Falzetti F, Carotti A etal. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.